{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:16:36Z","timestamp":1793132196800,"version":"4.5.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recombinant Adeno-associated virus (rAAV) is one of the main delivery vectors for gene therapy. To assess immunogenicity, toxicity, and features of AAV gene therapy in clinical settings, a meta-analysis of 255 clinical trials was performed. A total of 7,289 patients are planned to be dosed. AAV2 was the most dominantly used serotype (29.8%, n=72), and 8.3% (n=20) of trials used engineered capsids. 38.7% (n=91) of trials employed neutralizing antibody assays for patient enrollment, while 15.3% (n=36) used ELISA-based total antibody assays. However, there was high variability in the eligibility criteria with cut-off tiers ranging from 1:1 to 1:1,600. To address potential immunogenicity, 46.3% (n=118) of trials applied immunosuppressants (prophylactic or reactive), while 32.7% (n=18) of CNS and 37.5% (n=24) of ocular-directed trials employed immunosuppressants, possibly due to the immune-privileged status of CNS and retina. There were a total of 11 patient deaths across 8 trials, and 18 out of 30 clinical holds were due to toxicity findings in clinical studies. 30.6% (n=78) of trials had treatment-emergent serious adverse events (TESAEs), with hepatotoxicity and thrombotic microangiopathy (systemic delivery) and neurotoxicity (CNS delivery) being the most prominent. Additionally, the durability of gene therapy may be impacted by two distinct decline mechanisms: 1) rapid decline presumably due to immune responses; or 2) gradual decline due to vector dilution. The durability varied significantly depending on disease indication, dose, serotypes, and patient individuals. Most CNS (90.0%) and muscle trials (73.3%) achieved durable transgene expression, while only 43.6% of ocular trials had sustained clinical outcomes. The rAAV production system can affect rAAV quality and thus immunogenicity and toxicity. Out of 186 trials that have disclosed production system information, 63.0% (n=126) of trials used the transient transfection of the HEK293\/HEK293T system, while 18.0% (n=36) applied the baculovirus\/Sf9 (rBac\/Sf9) system. There were no significant differences in TESAEs and durability between AAV generated by rBac\/Sf9 and HEK293\/HEK293T systems. In summary, rAAV immunogenicity and toxicity poses significant challenges for clinical development of rAAV gene therapies, and it warrants collaborative efforts to standardize monitoring\/measurement methods, design novel strategies to overcome immune responses, and openly share relevant information.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1001263","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T01:32:15Z","timestamp":1666834335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":184,"title":["rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Weiran","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)77740-0","article-title":"Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus","volume":"351","author":"Wagner","year":"1998","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia b","volume":"371","author":"Nathwani","year":"2014","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia a","volume":"382","author":"Pasi","year":"2020","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia b gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"crossref","first-page":"e143780","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral immune response to AAV","volume":"4","author":"Calcedo","year":"2013","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.2174\/156652311796150354","article-title":"Immune responses to AAV in clinical trials","volume":"11","author":"Mingozzi","year":"2011","journal-title":"Curr Gene Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the complex story of immune responses to AAV vectors trial after trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adeno associated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"16083","DOI":"10.1038\/mtm.2016.83","article-title":"Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of treg induction upon hepatic AAV gene transfer","volume":"3","author":"Perrin","year":"2016","journal-title":"Mol Therapy-Methods Clin Dev"},{"key":"B16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/v11010038","article-title":"Methylation status of the adeno-associated virus type 2 (AAV2)","volume":"11","author":"T\u00f3th","year":"2019","journal-title":"Viruses"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103997","DOI":"10.1016\/j.cellimm.2019.103997","article-title":"TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy","volume":"346","author":"Ashley","year":"2019","journal-title":"Cell Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000369273","article-title":"Unique roles of TLR9-and MyD88-dependent and-independent pathways in adaptive immune responses to AAV-mediated gene transfer","volume":"7","author":"Rogers","year":"2015","journal-title":"J innate Immun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.101","article-title":"MyD88 signaling in b cells regulates the production of Th1-dependent antibodies to AAV","volume":"20","author":"Sudres","year":"2012","journal-title":"Mol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia b gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG motifs in rAAV genomes: Avoiding the toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon modification and PAMPs in clinical AAV vectors","volume":"28","author":"Wright","year":"2020","journal-title":"Tortoise Hare? Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675897","article-title":"Challenges posed by immune responses to AAV vectors: addressing root causes","volume":"12","author":"Hamilton","year":"2021","journal-title":"Front Immunol"},{"key":"B25","unstructured":""},{"key":"B26","unstructured":""},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991832","article-title":"A versatile toolkit for overcoming AAV immunity","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Systematic Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.10.018","article-title":"ZFN-mediated in vivo genome editing corrects murine hurler syndrome","volume":"27","author":"Ou","year":"2019","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"New Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"New Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia a","volume":"386","author":"Ozelo","year":"2022","journal-title":"New Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658399","article-title":"Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions","volume":"12","author":"Weber","year":"2021","journal-title":"Front Immunol"},{"key":"B37","unstructured":""},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"New Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.29139.bfs","article-title":"Profoundly saddened\u201d lysogene discloses child's death in phase II\/III trial","volume":"31","author":"Philippidis","year":"2020","journal-title":"Hum Gene Ther"},{"key":"B40","article-title":"AAV related immunological safety and toxicity: Preliminary clinical observations in the GAN and MTM1 trials","volume-title":"Presented at: Virtual workshop on systemic immunogenicity considerations of AAV-mediated gene therapy","author":"Bonnemann","year":"2020"},{"key":"B41","unstructured":""},{"key":"B42","unstructured":""},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1089\/gen.40.08.05","article-title":"Moving forward after two deaths in a gene therapy trial of myotubular myopathy: To learn from these tragedies, the scientific community must commit to full transparency and cooperation","volume":"40","author":"Wilson","year":"2020","journal-title":"Genet Eng Biotechnol News"},{"key":"B44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Re:\u201cMoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d","author":"Shieh","year":"2020","journal-title":"by Wilson Flotte Hum Gene Ther 31(15-16)"},{"key":"B45","unstructured":""},{"key":"B46","year":""},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13416","article-title":"Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: trials, future directions and safety considerations","volume":"47","author":"Ramlogan-Steel","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.750586","article-title":"Gene therapy in inherited retinal diseases: an update on current state of the art","volume":"8","author":"Amato","year":"2021","journal-title":"Front Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-4939-9065-8_5","article-title":"Aav production using baculovirus expression vector system","author":"Sandro","year":"2019","journal-title":"In Viral Vectors Gene Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Cl\u00e9ment","year":"2016","journal-title":"Mol Therapy-Methods Clin Dev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.050","article-title":"Human and insect cell-produced recombinant adeno-associated viruses show differences in genome heterogeneity","volume":"33","author":"Tran","year":"2022","journal-title":"Hum Gene Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.omtm.2020.05.018","article-title":"Methods matter: standard production platforms for recombinant AAV produce chemically and functionally distinct vectors","volume":"18","author":"Rumachik","year":"2020","journal-title":"Mol Therapy-Methods Clin Dev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.08.003","article-title":"Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells","volume":"25","author":"Kondratov","year":"2017","journal-title":"Mol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666666","article-title":"T Cell-mediated immune responses to AAV and AAV vectors","volume":"12","author":"Ertl","year":"2021","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.258","article-title":"Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors","volume":"21","author":"Mimuro","year":"2013","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e139881","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1704766114","article-title":"Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum igg and neutralizing factors against adeno-associated virus (Aav) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using aav vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.3.1524-1532.2000","article-title":"Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes","volume":"74","author":"Halbert","year":"2000","journal-title":"J Virol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"eabd0321","DOI":"10.1126\/sciadv.abd0321","article-title":"Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles","volume":"7","author":"Ilyinskii","year":"2021","journal-title":"Sci Adv"},{"key":"B65","unstructured":""},{"key":"B66","doi-asserted-by":"crossref","first-page":"eabb5413","DOI":"10.1126\/scitranslmed.abb5413","article-title":"Slowing late infantile batten disease by direct brain parenchymal administration of a rh. 10 adeno-associated virus expressing CLN2","volume":"12","author":"Sondhi","year":"2020","journal-title":"Sci Trans Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J Hepatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-associated virus-induced dorsal root ganglion pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum Gene Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"eaba9188","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci Trans Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J Virol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/ng1179","article-title":"AAV serotype 2 vectors preferentially integrate into active genes in mice","volume":"34","author":"Nakai","year":"2003","journal-title":"Nat Genet"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.007","article-title":"Encouraging and unsettling findings in long-term follow-up of AAV gene transfer","volume":"28","author":"Herzog","year":"2020","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum Gene Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Invest"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904514106","article-title":"Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy","volume":"106","author":"Brantly","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.053","article-title":"Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing \u03b11-antitrypsin: interim results","volume":"22","author":"Flotte","year":"2011","journal-title":"Hum Gene Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.169","article-title":"Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy","volume":"25","author":"Ferreira","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity\u2013\u2019one and done\u2019or \u2018slower and lower\u2019","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300299","article-title":"AAV vectors, insertional mutagenesis, and cancer","volume":"15","author":"Russell","year":"2007","journal-title":"Mol Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus (AAV) integration: An integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"key":"B84","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia a identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.031","article-title":"AAV integration in human hepatocytes","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J Clin Invest"},{"key":"B87","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ymthe.2020.12.031","article-title":"Enhanced efficacy and increased long-term toxicity of CNS-directed, AAV-based combination therapy for krabbe disease","volume":"29","author":"Li","year":"2021","journal-title":"Mol Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4199-14.2015","article-title":"Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy","volume":"35","author":"Hawkins-Salsbury","year":"2015","journal-title":"J Neurosci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.03.009","article-title":"Liver gene therapy and hepatocellular carcinoma: A complex web","volume":"29","author":"de Jong","year":"2021","journal-title":"Mol Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e0225206","DOI":"10.1371\/journal.pone.0225206","article-title":"Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP. b capsids","volume":"14","author":"Huang","year":"2019","journal-title":"PLoS One"},{"key":"B92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2019.02.013","article-title":"The GPI-linked protein LY6A drives AAV-PHP. b transport across the blood-brain barrier","volume":"27","author":"Hordeaux","year":"2019","journal-title":"Mol Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. blood","volume":"110","author":"Mingozzi","year":"2007","journal-title":"J Am Soc Hematol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. blood","volume":"121","author":"Martino","year":"2013","journal-title":"J Am Soc Hematol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.07.011","article-title":"An observational study from long-term AAV re-administration in two hemophilia dogs","volume":"10","author":"Sun","year":"2018","journal-title":"Mol Therapy-Methods Clin Dev"},{"key":"B96","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/humc.2017.014","article-title":"Non-clinical study examining AAV8. TBG. hLDLR vector-associated toxicity in chow-fed wild-type and LDLR+\/\u2013 rhesus macaques","volume":"28","author":"Greig","year":"2017","journal-title":"Hum Gene Ther Clin Dev"}],"updated-by":[{"DOI":"10.3389\/fimmu.2022.1104646","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1001263\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:23:22Z","timestamp":1674041002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1001263\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":96,"alternative-id":["10.3389\/fimmu.2022.1001263"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1001263","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"article-number":"1001263"}}